Itraconazol Stada

Itraconazole, the active ingredient in Itraconazol Stada, is an azole antifungal presented as an oral formulation for oral use. It treats a range of superficial and systemic fungal infections, including onychomycosis, aspergillosis, blastomycosis, and candidiasis, in adult patients as prescribed by a healthcare professional.

GNH USA supplies Itraconazol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole belongs to the azole class and is used to manage fungal infections affecting the skin, nails, and internal organs.

- Superficial mycoses: resolves skin and mucosal fungal infections such as tinea and oral candidiasis. - Systemic mycoses: treats deep‑seated infections including aspergillosis, blastomycosis, and disseminated candidiasis. - Onychomycosis: eradicates fungal infection of the toenails and fingernails, improving nail appearance and health.

Adverse reactions may occur with itraconazole therapy and should be monitored.

Common Side Effects: - Nausea - Abdominal pain - Headache - Rash

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Severe skin reactions such as Stevens‑Johnson syndrome - Cardiac failure or worsening of existing heart failure

Before initiating itraconazole, clinicians should consider several safety measures.

- Liver function monitoring: obtain baseline hepatic enzymes and repeat periodically. - CYP3A4 interactions: avoid concomitant use of strong inhibitors or inducers without adjustment. - Hypersensitivity: discontinue if signs of allergic reaction appear. - Cardiac risk: use with caution in patients with existing heart failure. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Itraconazole has a notable interaction profile that requires careful management.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) – may increase itraconazole levels. - Rifampin and other CYP3A4 inducers – may reduce efficacy. - St. John's wort – potent inducer that can markedly lower drug exposure.

Moderate Interactions (Monitor Closely): - Warfarin – may enhance anticoagulant effect, monitor INR. - Digoxin – increased serum concentrations possible. - Statins (especially simvastatin) – risk of myopathy, consider dose adjustment. - Oral contraceptives – efficacy may be reduced, advise alternative contraception.